Buy Bausch Health

Logo for stock BHC (Bausch Health)

Amount

£
GBP

Latest price

$7.26
(£1.00 = $1.348)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$3.742B

P/E ratio

38.49

EPS

$0.263

Beta

0.52

Dividend rate

N/A

Dividend yield

N/A

About

Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter (OTC) products and ophthalmic surgical devices and instruments. The Salix segment consists of sales in the U.S. of gastroenterology products. The International segment consists of sales, except for sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Diversified segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Bausch + Lomb segment includes Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.

CEO

Mr. Thomas J. Appio

Employees

20,700

Sector

Health

Company HQ

LAVAL, Canada

News

Logo for news article #0 (Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025)

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) today announced that BHC Lyon Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Bausch Health Americas, Inc. ("BHA"), and an indirect subsidiary of Bausch Health Companies Inc. ("BHC"), has extended the expiration date of its tender offer (the "Offer") to acquire all of the outstanding shares of common stock of DURECT Corporation for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million at closing, with the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestones are achieved before the earlier of the 10 year anniversary of the first commercial sale of larsucosterol (5-cholesten-3ß, 25-diol 3-sulfate sodium salt) in the United States and December 31, 2045. The Offer, which was previously scheduled to expire at 5:00 p.m.

Accesswire

August 26, 2025

Logo for news article #1 (Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan)

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Quebec and Saskatchewan. This new public drug plan availability of CABTREO is in addition to that announced last month for those using the Ontario and Nova Scotia public drug plans as well as through the federal government's Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations as well as those of the Correctional Service of Canada (CSC) and Veterans Affairs Canada.

Accesswire

August 21, 2025

Logo for news article #2 (Bausch + Lomb board members resign after Icahn agreement ends)

Bausch + Lomb board members resign after Icahn agreement ends

Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.

Reuters

August 18, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.